News

Novavax, Inc. announced its submission to the Singapore Health Sciences Authority (HSA) for interim authorization of its COVID-19 vaccine under the Pandemic Special Access Route (PSAR).…
Read More...

Donaldson Company, Inc. announced it acquired Solaris Biotechnology Srl (“Solaris”). Solaris designs and manufactures bioprocessing equipment, including bioreactors, fermenters and…
Read More...

Valneva SE, a specialty vaccine company, today announced that it has signed an Advance Purchase Agreement (APA) with the European Commission (EC) to supply up to 60 million doses of its…
Read More...

Nykode Therapeutics (formerly Vaccibody*)), a clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies, announced today…
Read More...

AstraZeneca will today, in the presence of His Royal Highness The Prince of Wales, formally unveil The Discovery Centre (DISC) in Cambridge, UK – a state-of-the-art research and…
Read More...

Gilead Sciences, Inc. announced that the European Commission (EC) has granted marketing authorization for Trodelvy (sacituzumab govitecan), a first-in-class Trop-2-directed…
Read More...

The U.S. Food and Drug Administration approved Livtencity (maribavir) as the first drug for treating adults and pediatric patients (12 years of age and older and weighing at least 35…
Read More...

Oncotelic Therapeutics, Inc. announced that its COVID-19 trial (“C001”) for OT-101 has successfully met its safety and efficacy endpoints. OT-101 is a first-in-class anti-TGF-β…
Read More...

Valneva SE a specialty vaccine company, today announced that it has signed an Advance Purchase Agreement (APA) with the European Commission (EC) to supply up to 60 million doses of its…
Read More...

Nykode Therapeutics (formerly Vaccibody*)), a clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies, announced that…
Read More...

BioNTech SE announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation for BNT111, an investigational cancer immunotherapy for the potential treatment of…
Read More...

Neurocrine Biosciences, Inc. and Sosei Group Corporation announce the signing of a strategic collaboration and licensing agreement to develop novel muscarinic receptor agonists, which…
Read More...

Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, announced it entered into a…
Read More...

Obseva SA, a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, announced that the New Drug Application (NDA) for…
Read More...

Vifor Pharma has announced the acquisition of Sanifit Therapeutics, a Spanish clinical-stage cardio-renal biopharmaceutical company focused on treatments for end-stage kidney disease…
Read More...

REGENXBIO Inc. announced the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for RGX-202, a potential one-time gene therapy for the treatment of Duchenne…
Read More...

Arrowhead Pharmaceuticals Inc. announced that it entered into an exclusive license agreement with GlaxoSmithKline under which GSK will develop and commercialize ARO-HSD, Arrowhead’s…
Read More...

Xencor, Inc. a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, and Zenas…
Read More...

CStone Pharmaceuticals, a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies and precision medicines,…
Read More...

Gilead Sciences, Inc. and Arcus Biosciences, Inc. announced that Gilead has exercised its options to three programs in Arcus’s clinical-stage portfolio, including both anti-TIGIT…
Read More...